Bio€quity Europe 2017

Published on 17/01/2017

22-23 May, 2017

Paris, France

Bio€quity Europe pioneered the turf-neutral concept, creating an open door for all members of the financial community and business development and licensing professionals to do business with independently selected Presenting Companies.

Now celebrating its 18th meeting, Bio€quity Europe is the seminal industry event for financial dealmakers looking for investor-validated life science companies positioning themselves to attract capital, and for pharmaceutical licensing professionals to assess top prospects. Bio€quity Europe has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals. Delegates from over 20 nations attended Bio€quity Europe last year.

http://www.biocentury.com/conferences/bioequityeurope/dates>

• The 2024 international workshop on Alport syndrome
• ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
• 6th CKD Summit – Chronic Kidney Disease Drug Development
• ASN Kidney Week
• Alport Connect 2023, the annual Alport syndrome patient and family meeting in US